A major obstacle in cancer therapy is the damage to normal organs by conventional chemotherapy and radiotherapy. This highlights the need for therapy that specifically target and kill cancer cells while sparing normal cells. One emerging target is GRP78, which is preferentially expressed on cancer cell surface and promotes tumor cell survival and metastasis.
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STATEMENT OF TRANSLATIONAL RELEVANCE
A major obstacle in cancer therapy is the damage to normal organs by conventional chemotherapy and radiotherapy. This highlights the need for therapy that specifically target and kill cancer cells while sparing normal cells. One emerging target is GRP78, which is preferentially expressed on cancer cell surface and promotes tumor cell survival and metastasis.
We have developed a monoclonal antibody MAb159 against GRP78 to target surface GRP78 and block its oncogenic functions. MAb159 effectively images tumors in vivo, suppresses PI3K/AKT signaling, induces apoptosis, and induces tumor regression in xenografts and spontaneous tumor models. The humanized MAb159 retains its GRP78 binding affinity and efficacy and is non-toxic to normal organs. We plan to initiate human clinical trial shortly. 
INTRODUCTION
Cancer cells are characterized by metabolic alterations and the tumor microenvironment is often marked with impaired blood flow and hypoxia, all of which can elicit endoplasmic reticulum (ER) stress. Tumor cells adapt to these adverse conditions by activating the unfolded protein response (UPR), with induction of GRP78 as a major pro-survival arm of the UPR signaling pathways (1, 2) . GRP78, also referred to as BiP/HSPA5, is a 78 kilodalton glucose regulated protein with potent anti-apoptotic properties that plays critical roles in cancer cell survival, tumor progression, metastasis and resistance to therapy (3) (4) (5) . Knockdown of GRP78 by siRNA in cancer cells as well as tumor associated endothelial cells reduced their proliferative rate and sensitize them to chemotherapeutic treatment (6, 7) . Genetically altered GRP78 mouse models further demonstrated the critical role of GRP78 in cancer in vivo. For instance, GRP78 haploinsufficiency delayed tumor development, growth and inhibited metastasis. (8, 9) . In mice harboring biallelic conditional knockout of both GRP78 and tumor suppressor PTEN in the prostate epithelium, prostate tumorigenesis was potently arrested (10) . Inducible heterozygous knockout of GRP78 in the hematopoietic system also suppresses PTEN-null leukemogenesis with no harmful effect on hematopoiesis (11) . Strikingly, in both the prostate and leukemia models, PI3K/AKT signaling resulting from the loss of PTEN was greatly impaired with only partial loss of GRP78 (10, 11) . Collectively, these studies establish GRP78 as a novel regulator of the PI3K/AKT oncogenic signaling and a target for anti-cancer therapy.
While traditionally GRP78 has been regarded as an ER lumenal protein, evidence has accumulated that a fraction of GRP78 can exist on the plasma membrane of specific cell types (12) (13) (14) and that ER stress actively promotes cell surface localization of GRP78 (15) . While the physiological function of GRP78 on the cell surface is still emerging, recent studies show that
Research. cell surface GRP78 forms complexes with specific protein partners, regulating both proliferation and viability (14, 16) , suggesting that cell surface GRP78 presents an opportunity for therapeutic targeting (17) (18) (19) .
Here we report the generation of a monoclonal antibody (MAb159) against human GRP78 that shows anti-tumor activity with no toxicity and also inhibits PI3K signaling. This antibody opens up a unique opportunity to study both the biology of cell surface GRP78 and its therapeutic potential.
MATERIALS AND METHODS
Antibodies, reagents, and cell lines
A549, HT29, Colo205, LNCap, MCF7, 4T1, and 293T cell lines were obtained from American Type Culture Collection (Manassas, VA). C4-2B cell was kindly provided by Michael Stallcup (USC) and H249 was kindly provided by Dr. Ravi Salgia in University of Chicago. The generation of the B16-Fluc-A1 melanoma cell line has been described (9) . All these cells were propagated in RPMI-1640 supplemented with 10% fetal bovine serum, 100 units/ml of penicillin, and 100 µg/ml streptomycin from Cellgro (Manassas, VA). CE1 cell line was kindly provided by Dr. Pradip Roy-Burman and cultured as previously described (20) . These cell lines have been validated by HLA typing and molecular phenotyping relative to the respective primary tumors.
Information about antibodies and reagents used in this study can be found in the "Supplementary Methods".
Generation of monoclonal antibodies and affinity analysis
Research. The procedure for generation of monoclonal antibodies is described in "Supplementary Methods". The affinity of MAbs to antigen was determined by Scatchard assay as described previously (21) .
In vivo and ex vivo near-infrared fluorescence imaging
H249 tumor bearing mice were injected with Cy5.5 labeled humanized MAb159 or control antibody. In vivo fluorescence imaging was performed using the Xenogen Lumina XR Imaging System and analyzed using the IVIS Living Imaging 3.0 software. 28 hours after injection, the tumors and organs were harvested for ex vivo fluorescence imaging. Please see "Supplementary
Methods" for detailed procedure.
PTEN-null models
The prostate specific PTEN knock out model was described previously (22) . Mice were treated with MAb159 and prostate tumors were monitored by luminescence imaging (xenogen). The Pten (floxed/floxed); Mx-1 cre leukemic model and the protocols for flow cytometry for analysis of leukemic blasts and peripheral blood counts have been described (11) . Please see "Supplementary Methods" for detailed procedure.
Murine tumor xenograft models
The procedures for murine tumor xenograft studies and immunohistochemical analysis were as before (21) and described in "Supplementary Methods".
Statistics
The statistical significance of differences in different samples or groups was determined using a unpaired 2-tail student T-test. Results were considered significantly different if P < 0.05.
Research. 
RESULTS
Generation of monoclonal antibodies (MAbs) specific to surface GRP78
We immunized mice with a hexahistidine tagged and secreted form of human GRP78 ( Figure   S1A ), and screened a panel of MAbs capable of binding the native form of GRP78. The criteria for the desirable antibody were high affinity binding to native cell surface GRP78 and the ability to endocytose. MAb159 fulfilled these requirements. MAb159 is highly specific for GRP78 as the binding of MAb159 to GRP78 was completely abolished by purified soluble GRP78 protein ( Figure S1B ). We also performed immunoprecipitation study with MAb159 and confirmed that GRP78 can be pulled down from cell lysate using mass spectrometry analysis (data not shown).
MAb159 has no cross-reactivity to GRP78's closest paralogue HSP70 ( Figure S1C ), but it recognizes mouse GRP78, which is 99% conserved in amino acids with human GRP78 ( Figure   S1D ). Using scatchard analysis we have determined that MAb159 has high affinity to human GRP78 (Kd=1.7nM) ( Figure S1E ), hence suitable for therapeutic development. When incubated with cultured cells at 4°C, MAb159 bound the cell surface of cancer cells, but not to normal human dermal fibroblasts ( Figure 1A , left). Under glucose starvation conditions which mimicked nutrient deprivation in the tumor microenvironment, greater amount of MAb159 was recruited to cancer cell surface. This is consistent with the previous findings that surface GRP78 significantly increases when the cell is under stress (14, 15) . We also determined whether MAb159 preferably localizes to tumor and not normal organs by tracking biotin labeled MAb159 in HT29 xenograft tumor bearing mice in vivo. Biotin-MAb159 was only seen in the tumor, not in the normal organs including heart, liver, and kidney ( Figure 1A, right) . Figure S2A ). We next examined the surface GRP78 level with a second antibody and found that surface GRP78 was markedly reduced after MAb159 treatment ( Figure 1B, bottom) . Moreover, this reduction of GRP78 can be reverted with chlorpromazine ( Figure S2B ), an inhibitor specific for clathrin-mediated endocytosis (23) . These data implicate that MAb159 led to internalization of surface GRP78.
MAb159 induces tumor cell apoptosis and inhibits PI3K signaling
The effect of MAb159 on tumor cells was first tested in vitro. Before incubated with MAb159, breast carcinoma cell MCF7 and colon cancer cell HT29 were cultured in glucose-free medium to enhance surface GRP78 level and thus the efficacy of the antibody. Figure S3B ). We have also measured activated caspase levels and showed that MAb159 treatment activates caspase 8 and 9 ( Figure S3C ), which represent the activation of extrinsic and intrinsic apoptotic pathways, respectively. This suggests that at least in part the loss of cell viability was initiated at the cell membrane.
PI3K signaling pathway regulates many biological events in the cells including cell survival and GRP78 has previously been shown to modulate its activity. Therefore, we examined whether MAb159 treated cell surface GRP78 expressing tumor cells have alterations in PI3K activity as measured by the changes in phosphorylated AKT and S6 levels. We indeed found that both phosphorylated AKT and S6 levels were reduced in antibody treated cells compared to the controls ( Figure 1D ). Since MAb159 induced GRP78 endocytosis led to loss of cell surface GRP78 and inhibition of pAKT signaling, we anticipate that blocking GRP78 endocytosis would antagonize MAb159's activity. We however were unable to conduct this experiment because Chropromazine by itself reduces pAKT levels and causes cellular toxicity ((24) and data not shown).
The above results indicate that MAb159 inhibits PI3K pathway and induces cell apoptosis, which is consistent with the recent indication that cell surface GRP78 may be an upstream regulator of PI3K/AKT but not MAPK signaling (14) . We thus wished to determine if there is a direct interaction between cell surface GRP78 and PI3K components. We expressed a FLAG tagged GRP78 with KDEL deletion for enhanced translocation to the cell surface (15) , labeled the cell surface proteins with biotin and purified the biotin labeled proteins on monomeric avid beads. GRP78 was immunoprecipitated from this pool of surface proteins and its interacting partners were detected by Western blotting. As seen in Figure S4A , GRP78 formed complex with p85, the regulatory subunit of PI3K, but not with ERK1/2 or a cell surface specific protein EphB2. We further confirmed this interaction under endogenous expression condition. Surface GRP78 was induced with thapsigargin (15) and cell surface proteins were enriched using biotinavidin system. Co-immunoprecipitation of surface GRP78 and p85 was achieved with either GRP78 antibody or p85 antibody ( Figure S4B ). These results provide the first evidence that surface GRP78 binds to PI3K component and suggest surface GRP78 regulates PI3K signaling through direct complex formation with the PI3K subunits.
MAb159 inhibits tumor growth and causes tumor regression in various xenograft tumor models
Research. The efficacy of GRP78 antibody MAb159 in vivo was examined in various tumor xenograft models including HT29 (colon cancer), H249 (small cell lung carcinoma), and A549 (lung adenocarcinoma). These cells have relatively high (4.6-9.4%, Figure S5 ) surface GRP78 expression compared to normal cells (15) . MAb159 treatment led to 50%, 58%, and 78% tumor growth inhibition in these models, respectively (Figure 2A ).
To further test if the combination of GRP78 targeted therapy and conventional chemotherapy leads to greater efficacy, we combined MAb159 and Irinotecan in a colon cancer xenograft model. Colon cancer model was chosen because GRP78 overexpression was reported to be associated with colorectal carcinogenesis (25) . When administrated alone, MAb159 inhibited tumor growth by 54% compared to control group. Irinotecan mono-therapy inhibited tumor growth by 85%. The combination therapy caused tumor regression to 47% of the starting tumor volume (Figure 2A ).
MAb159 reduces proliferation, induces apoptosis, impairs tumor vasculature, and inhibits
PI3K signaling in tumor xenografts
At the end of the xenograft experiments, tumors were harvested for analysis. In MAb159 treated group, proliferation index (Ki67 staining) was markedly reduced, apoptosis (TUNEL assay) was significantly increased (Figure 2B ), and vessel density (CD31 staining) had a modest decrease antibody was well tolerated measured by the animal food intake, body weight (data not shown) and microscopic examination of vital organs ( Figure S7 ).
MAb159 inhibits tumor metastasis
GRP78 promotes growth of blood vessels in the tumor accompanied by tumor growth and metastasis (9) . Targeting surface GRP78 with a peptide conjugated to pro-apoptosis molecules inhibits metastases (19) . Therefore, we tested MAb159 in an orthotopic tumor model using mouse breast adenocarcinoma cell 4T1 (26, 27) . 4T1 cells were implanted into the #4 fat pads of isogenic BALB/c mice, which were treated bi-weekly with MAb159 at 10 mg/kg or saline. 
We also examined the effect of MAb159 on the metastatic growth of a syngeneic melanoma cancer cell line (9) . B16-Fluc-A1 melanoma cells stably expressing luciferase were injected intravenously. Tumor metastasis and progression in the lungs was monitored live with a whole animal luminescence imaging system. MAb159 treatment significantly reduced the lung tumor formation (Figure 3C, left) . At the end of the experiment, lungs were harvested and pigmented tumors were observed on the lung surface. Compared to the control group, the lungs from MAb159 treated mice had significantly fewer tumors ( Figure 3C , right).
MAb159 suppresses PTEN deletion induced prostate cancer progression and leukemogenesis
We tested MAb159 in the setting of constitutively active PI3K in the PTEN knockout spontaneous tumor models including inducible PTEN knock out in prostate and hematopoietic system. In PTEN knockout spontaneous prostate cancer model, PTEN deletion is achieved with induction of Cre under probasin promoter. The luciferase expression is also induced by the same Cre so PTEN deficient prostate cells can be imaged with a luminescence imaging system (22) .
Tumor develops in prostate in 2-3 months. Control IgG or MAb159 was given to 2 month old PTEN null mice three times a week at 10 mg/kg dose. Tumor progression was monitored with live animal luminescence imaging. In MAb159 treated group, there was marked tumor regression ( Figure 4A ). In contrast, mice in control IgG treated group uniformly progressed. Histological analysis of dorsolateral prostate indicates that control IgG treated prostate had extensive adenocarcinoma ( Figure 4B ). In contrast, MAb159 treated prostate only had mild prostate interepithelial neoplasia ( Figure 4B ). Further immunohistochemical analysis shows that MAb159 significantly reduced pAKT and pS6 levels, suggesting inhibition of PI3K signaling ( Figure 4B ). 
Affinity, Activity, and Specificity of Humanized MAb159
We have selected the antibody with the desired features suitable for therapeutic development.
Next we made humanized MAb159 to avoid potential immunogenicity in humans. This antibody has affinity to GRP78 ( Figure 6A ) and efficacy in tumor growth inhibition ( Figure 6B) comparable to the parental murine antibody. 
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To determine the tumor specific localization of humanized MAb159, we imaged tumorbearing live mice injected with Cy5.5-labeled humanized MAb159. We found that 28 hours after injection, humanized MAb159 preferentially localized to H249 tumors but not to mouse organs ( Figure 6C, left) . At the end of the study, the normal organs along with tumors were harvested for an ex vivo imaging. There was a dramatic difference in the signal intensity in tumor between control IgG and humanized MAb159 (Figure 6C, right) . The tissues were further subjected to immunohistochemistry analysis using a human Fc specific antibody, confirming the specific localization of humanized MAb159, but not control IgG to tumor ( Figure 6D ).
Pharmacokinetics and toxicology studies of humanized MAb159
We performed pharmacokinetics and toxicology studies of humanized MAb159 in mouse. A single 10 mg/kg dose of humanized Mab159 was administered i.v. and serum levels of the antibody were measured at designated time points. The mean maximum serum concentration (Cmax) of 61.5 μg/mL was achieved. The mean serum half-life was over 3 days (Table S1 ). At 10 mg/kg of humanized MAb159, an area under curve (AUC) of 4045 ± 1026 µg*hr/mL was achieved. Toxicology study was conducted in C57BL/7 mice treated 2 times a week for 5 weeks with 10 mg/kg humanized MAb159. Overall, there was no significant toxicity found in either the blood or vital organs of humanized MAb159 treated mice (Table S2) Cell surface GRP78 is a multifunctional receptor and a potential target for cancer therapy. For example, pro-apoptotic moieties or cytotoxic agents were conjugated onto peptides with high affinity for GRP78 to successfully target and kill cancer cells (12, 19) . Recently an unconjugated peptidic GRP78 ligand also demonstrated toxicity to prostate cancer cell (29) . A human monoclonal IgM antibody against cell surface GRP78 isolated from a cancer patient is capable of inducing lipid accumulation and apoptosis in cancer cells (30) . Here we screened and identified a novel monoclonal antibody which recognizes both human and mouse GRP78 with high specificity and potently inhibits tumor growth and causes tumor regression in xenograft tumor models and spontaneous tumor models. MAb159 also suppresses tumor metastasis in multiple models. Furthermore, the humanized form of this antibody is efficacious and without toxicity.
Cell surface GRP78 is an upstream regulator of PI3K/AKT signaling. GRP78 interacts with
Cripto and α₂-macroglobulin on cell surface and is required for these factors to activate downstream PI3K/AKT signaling (16, 31, 32) . Recently, a murine monoclonal antibody against GRP78 was reported to suppress AKT activation in a melanoma model (33) . Here we show that surface GRP78 is in the same complex as the p85 subunit of PI3K, and treatment of cells with the GRP78 specific antibody MAb159 led to marked reduction in PI3K signaling in both cultured cells and in multiple tumor models. The spontaneous tumor models include PTEN deletion induced spontaneous prostate cancer and leukemia models. Furthermore, in tumor xenografts subjected to long term treatment with MAb159 for up to 30 days, inhibition of PI3K pathway was sustained and there was no evidence for induction of escape mechanisms of resistance to PI3K inhibition such as MAPK (34) . Altogether, these highlight the importance of surface GRP78 in PI3K/AKT signaling and support the clinical investigation of MAb159 for PI3K driven tumors. However, cell surface GRP78 may also regulate other critical oncogenic 
pathways. For example, MAb159 is active to cell lines with Kras mutation (A549) and Braf mutation (HT29 and Colo205). In light of MAb159's pro-apoptotic activity, we are also investigating the role of surface GRP78 in the extrinsic apoptosis pathway.
Recent studies reported that surface GRP78 is highly elevated in tumor associated vasculature and required for endothelial cell proliferation and survival (7, 9) . These findings indicate that cell surface GRP78 targeting agents will have dual function: targeting tumor cell and tumor vasculature. Consistently, we have observed that MAb159 reduced the tumor endothelial cell density and angiogenesis dependent tumor metastasis, supporting dual targeting.
Antibody tracking and in vivo imaging studies showed that MAb159 is strictly localized to the tumor and not normal organs, indicating that antibody targeting is highly specific. In agreement with this, formal toxicology study in mice showed that the humanized antibody was well tolerated and did not induce any noticeable organ toxicity or changes in blood counts or blood chemistry.
Another potential application of MAb159 lies in its ability to be used for in vivo imaging.
MAb159 specifically recognizes surface GRP78, and thus can be used to image the tumor for personalized medicine and determine whether the amount of surface GRP78 in the tumor predicts disease progression and response to therapy. Clinical trials will incorporate patient imaging as a screening process for inclusion of study subjects. This is particular important in cell surface GRP78 targeted therapy: when analyzing archival tumor samples with immunostaining, intracellular GRP78 will interfere with such analysis.
In conclusion, we have developed a novel antibody MAb159 targeting surface GRP78 Signal was quantified with Image J. Quantification data are presented as mean ± standard error of the mean (SEM) (n=4). Double asterisks indicate P < 0.002, as determined by an unpaired 2-tail student T-test. Scale bar, 100 μm. 
